Two-drug therapy before surgery for early triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs given before surgery for early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink tumors and improve outcomes while possibly reducing the need for more intensive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage II or III triple-negative breast cancer that has not spread to other parts of the body.
- You have not had any prior treatment for this cancer (such as surgery, radiation, or chemotherapy).
- You are generally in good health, with adequate organ function (kidney, liver, blood counts).
- You do not have active infections, autoimmune diseases, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This trial tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. The treatment is given before surgery to shrink the tumor and make surgery more effective.
This study tests a new combination of two medicines (SHR-A2102 and adebrelimab) given before surgery to treat early-stage triple-negative breast cancer. This approach aims to shrink the tumor and potentially improve the chances of a cure.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial is testing whether giving a combination of two medicines before surgery can help shrink or eliminate tumors in people with triple-negative breast cancer (a type of breast cancer that lacks certain receptors). The goal is to see if this approach improves outcomes compared to the usual approach.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
Hear when a new TNBC, Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.